Pacifica Partners’s Novo Nordisk NVO Stock Holding History

Pacifica Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.72K	Hold	153	–	–	﹤0.01%	328
2026 Q1	$5.62K	Hold	153	–	–	﹤0.01%	352
2025 Q4	$8.02K	Buy	153 +43	+39%	+$2.2K	﹤0.01%	318
2025 Q3	$6.51K	Buy	110 +86	+358%	+$5.03K	﹤0.01%	369
2025 Q2	$1.64K	Hold	24	–	–	﹤0.01%	485
2025 Q1	$1.61K	Buy	+24	New	+$1.98K	﹤0.01%	461
2023 Q4	–	Sell	-480	Closed	-$43.2K	–	566
2023 Q3	$43.2K	Hold	480	–	–	0.02%	206
2023 Q2	$38.4K	Hold	480	–	–	0.02%	187
2023 Q1	$38.1K	Sell	480 -450	-48%	-$31.9K	0.02%	192
2022 Q4	$62K	Hold	930	–	–	0.04%	144
2022 Q3	$46K	Sell	930 -126	-12%	-$6.75K	0.03%	169
2022 Q2	$58K	Buy	1,056 +930	+738%	+$51.6K	0.04%	163
2022 Q1	$7K	Hold	126	–	–	﹤0.01%	343
2021 Q4	$6K	Hold	126	–	–	﹤0.01%	353
2021 Q3	$6K	Hold	126	–	–	﹤0.01%	347
2021 Q2	$5K	Buy	+126	New	+$4.88K	﹤0.01%	356

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

OFA

Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Pacifica Partners's NVO Position: Q2 2026 in Review

Pacifica Partners held its Novo Nordisk (NVO) position steady in Q2 2026 at 153 shares worth $7.72K. The position accounts for ﹤0.01% of the portfolio, ranked #328.

Pacifica Partners first reported a position in NVO in Q2 2021 and has held it in 16 quarters since. The position peaked at $62K in Q4 2022. 387 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Pacifica Partners held 153 shares of Novo Nordisk worth $7.72K as of Q2 2026.
Pacifica Partners left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up ﹤0.01% of Pacifica Partners's portfolio in Q2 2026, its #328 holding.
Pacifica Partners first reported a position in Novo Nordisk in Q2 2021 and has held it in 16 quarters since.
Pacifica Partners's Novo Nordisk position peaked at $62K in Q4 2022.
387 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Pacifica Partners's 13F filing for Q2 2026, filed 13 Jul 2026.